RBC Capital Reiterates Outperform on Neumora Therapeutics, Maintains $31 Price Target

Neumora Therapeutics, Inc. +7.34%

Neumora Therapeutics, Inc.

NMRA

9.50

+7.34%

RBC Capital analyst Brian Abrahams reiterates Neumora Therapeutics (NASDAQ: NMRA) with a Outperform and maintains $31 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via